Oral Wegovy tracker: FDA, EMA, MHRA

With the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approving oral semaglutide for weight management on 11 June 2026^[1], the tablet form of Wegovy has now cleared the three regulators that matter most to PeptideMethods readers: the FDA, the EMA, and the MHRA. This tracker sets out when each decision landed, what each regulator actually approved, and where access still depends on pricing and reimbursement bodies.

The timeline

The oral semaglutide story begins with Rybelsus, the 14 mg tablet approved for type-2 diabetes. The FDA cleared Rybelsus in September 2019. The EMA followed in April 2020^[4]. The MHRA, then operating under the EU regulatory framework, inherited the EMA authorisation. Rybelsus established that an oral GLP-1 receptor agonist could survive the stomach (via the absorption enhancer SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) and deliver clinically meaningful glycaemic effects. But its dose ceiling of 14 mg was not high enough for the weight-loss indication.

Novo Nordisk's OASIS clinical programme tested a higher oral semaglutide dose, 25 mg, specifically for weight management. The pivotal OASIS 4 trial enrolled 307 adults without diabetes who had obesity or overweight with at least one weight-related comorbidity, and reported 13.6% mean weight loss at 64 weeks versus 2.2% on placebo^[3]. On the back of those data, the FDA was first to approve the oral weight-management indication, in December 2025. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the oral formulation for weight management on 22 May 2026^[2]. The MHRA followed on 11 June 2026^[1].

What each regulator approved

All three agencies authorised the same core indication: adults with obesity (BMI of 30 or above) or overweight (BMI 27 to under 30) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. The maintenance dose is 25 mg once daily after a titration period starting at 1.5 mg^[1].

The EMA recommendation listed specific comorbidities: type-2 diabetes, hypertension, high cholesterol, cardiovascular disease, or obstructive sleep apnoea^[2]. The MHRA press release described the eligible population in similar terms but did not enumerate the qualifying comorbidities^[1]. In practice, prescribers in both jurisdictions will consult the full Summary of Product Characteristics for the specific criteria.

Approval does not mean access

Each regulatory green light opens a different path to patient access. In the US, FDA approval meant the product could be prescribed and dispensed immediately, and early data suggested that oral Wegovy prescriptions skewed heavily toward patients who had never used an injectable GLP-1, indicating the pill format was reaching a different population. In the EU, the CHMP opinion must be ratified by the European Commission (typically within two months), after which individual member states set pricing and reimbursement. National timelines vary widely; in some EU countries, reimbursement negotiations for injectable Wegovy took more than a year after EMA authorisation.

In the UK, the MHRA approval means the product meets safety and efficacy standards, but NHS prescribing depends on a separate evaluation by the National Institute for Health and Care Excellence (NICE). NICE has not yet published a technology appraisal for oral Wegovy^[1]. The MHRA noted that patients seeking the tablet would initially need to obtain it through private prescriptions. For comparison, NICE has previously appraised injectable Wegovy for weight management and injectable tirzepatide for both obesity and type-2 diabetes, so a similar process for the oral formulation is expected.

How the oral formulation fits the broader semaglutide regulatory picture

Semaglutide now spans three brand names across two delivery routes and multiple indications. Ozempic (injectable, type-2 diabetes) came first, approved by the EMA in January 2018 and the FDA in December 2017. Wegovy (injectable, weight management) followed with FDA approval in June 2021 and EMA authorisation in January 2022. Rybelsus (oral, type-2 diabetes) was the first oral GLP-1, reaching the market in 2019 in the US and 2020 in the EU^[4]. Oral Wegovy (oral, weight management) is the latest extension. The UK and EU authorise both the injectable and oral weight-management products under the Wegovy brand; the US does the same.

For regulatory status by country, see the semaglutide regulation pages and the UK regulation hub.

What is still pending

Three things to watch. First, NICE appraisal of oral Wegovy for NHS use in England and Wales, which will determine whether the tablet is prescribed on the NHS or remains private-only. Second, EU member-state pricing and reimbursement decisions, which will determine when (and whether) insured patients in Germany, the Netherlands, Denmark, and other markets can access the oral formulation without paying out of pocket. Third, whether any regulator extends the oral indication to adolescents, as the EMA has already done for injectable Wegovy in patients aged 12 and above^[2].

We will update this tracker as NICE, the European Commission, and national pricing bodies publish their decisions. For the most current per-country regulatory status, see the semaglutide country pages.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making decisions about weight management treatments.